Biologic therapy for uveitis

Houman D. Hemmati, James P. Dunn

Research output: Contribution to journalReview articlepeer-review

Abstract

Biologic agents have become a valuable tool in the treatment of uveitis. Clinical experience is greatest with the tumor necrosis factor antagonists, of which infliximab has been used the most extensively for ocular inflammatory disease. However, while results have been promising, especially for Adamantiades-Behets disease, few controlled studies have been published and uncontrolled studies have significant methodologic flaws. Serious side effects from these drugs may occur. Randomized controlled clinical trials comparing different biologic agents or the biologics to other immunosuppressive drugs are lacking. Adverse effects, expense and possible diminution of effect over time may all limit the usefulness of these drugs. Nonetheless, the development of biologic agents that target specific mediators of the inflammatory process holds enormous potential in the treatment of vision-threatening uveitis.

Original languageEnglish (US)
Pages (from-to)225-239
Number of pages15
JournalExpert Review of Ophthalmology
Volume5
Issue number2
DOIs
StatePublished - Apr 2010

Keywords

  • Adalimumab
  • Anakinra
  • Biologics
  • Daclizumab
  • Etanercept
  • Infliximab
  • Interferon
  • Interleukin
  • Ocular inflammation
  • TNF
  • Tumor necrosis factor
  • Uveitis

ASJC Scopus subject areas

  • Biomedical Engineering
  • Ophthalmology
  • Optometry

Fingerprint Dive into the research topics of 'Biologic therapy for uveitis'. Together they form a unique fingerprint.

Cite this